Rocket Pharmaceuticals heads into its May 11 earnings release carrying one of the heavier short burdens in the small-cap biotech space — and bears built most of that position in the last month alone.
Short interest is the defining feature of the current setup. At roughly 17.9% of the free float, the short position is substantial for a stock trading at $3.67. More striking is the pace: SI climbed nearly 24% in the past month, with the bulk of that increase arriving after April 9, when shares outstanding on loan jumped from around 15.7 million to over 19.3 million in a matter of days. Despite that surge in borrowed shares, borrow costs remain remarkably cheap at 0.46% annualised — down more than 20% over the month — and availability is loose, meaning the lending pool has ample room to absorb further short demand without a squeeze. The ORTEX short score of 63.8 reflects elevated but not extreme conviction from the short side.
Options positioning tells the opposite story. Call activity dominates the options market in an unusual way — the put/call ratio is running at just 0.07, slightly below its already-low 20-day average of 0.073 and well below the 52-week high of 0.44. That makes options traders among the more bullish-leaning participants in the market right now, a sharp contrast to the growing short book. The stock itself added 6% over the past week before giving back nearly 5% on Thursday alone, closing at $3.67.
The analyst debate centres on a single catalyst: the anticipated commercial launch of Kresladi and the monetisation of a Rare Pediatric Disease Priority Review Voucher. Bulls, including B of A Securities — which raised its target to $9 in late March — and Cantor Fitzgerald at $10, point to $150 million in potential non-dilutive capital from a PRV sale as a cash runway extender into mid-2027. Goldman Sachs sits on the other side with a Sell rating, raising its target to just $3 in early March — effectively flagging a view that the stock's fair value is at or below the current price. The mean analyst target of $8.84 implies more than 140% upside from current levels, but Goldman's $3 floor is a reminder that the Street is not reading from the same sheet. The bear case rests on manufacturing complexity for AAV and lentiviral therapies and the risk that one-time gene therapy pricing benchmarks against recurring orphan drug costs rather than the replacement-value ceiling.
Past earnings reactions at Rocket have been asymmetric. The February 2026 print delivered a 15.7% one-day jump and a further 7.2% over the following five days. The November 2025 event saw a modest 2.8% initial gain followed by a 4.1% pullback. The pattern shows the stock can move sharply but inconsistently — and with a high short float, any upside surprise carries additional fuel from potential short covering. Sunday's print will test whether the PRV sale timeline and Kresladi's commercial readiness are tracking to the bulls' schedule, or whether manufacturing realities are beginning to slip.
See the live data behind this article on ORTEX.
Open RCKT on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
